Document Detail

Overall and Cancer-Specific Survival of Patients With Breast, Colon, Kidney, and Lung Cancers With and Without Chronic Lymphocytic Leukemia: A SEER Population-Based Study.
MedLine Citation:
PMID:  23341508     Owner:  NLM     Status:  Publisher    
PURPOSEChronic lymphocytic leukemia (CLL) is associated with an increased risk of developing second cancers. However, it is unknown whether CLL alters the disease course of these cancers once they occur. PATIENTS AND METHODSAll patients with cancers of the breast (n = 579,164), colorectum (n = 412,366), prostate (n = 631,616), lung (n = 489,053), kidney (n = 95,795), pancreas (n = 82,116), and ovary (n = 61,937) reported to the SEER program from 1990 to 2007 were identified. Overall survival (OS; death resulting from any cause) and cancer-specific survival were examined, comparing patients with and without pre-existing CLL. Cancer-specific survival was evaluated for each tumor type in a site-specific manner (eg, death resulting from breast cancer in a patient with breast cancer).ResultsPatients with cancers of the breast (hazard ratio [HR], 1.70; P < .001), colorectum (HR, 1.65; P < .001), kidney (HR, 1.54; P < .001), prostate (HR, 1.92; P < .001), or lung (HR, 1.19; P < .001) had inferior OS if they had a pre-existing diagnosis of CLL after adjusting for age, sex, race, and disease stage. These results for OS remained significant for patients with cancers of the breast, colorectum, and prostate after excluding or censoring CLL-related deaths. Cancer-specific survival was also inferior for patients with cancers of the breast (HR, 1.41; P = .005) and colorectum (HR, 1.46; P < .001) who had pre-existing CLL after adjusting for age, sex, race, and disease stage. CONCLUSIONInferior OS and cancer-specific survival was observed for several common cancers in patients with pre-existing CLL. Additional studies are needed to determine the optimal management of these malignancies in patients with CLL and whether more aggressive screening or alternative approaches to adjuvant therapy are needed.
Benjamin M Solomon; Kari G Rabe; Susan L Slager; Jerry D Brewer; James R Cerhan; Tait D Shanafelt
Related Documents :
22882888 - Chapter 14: comparing the adequacy of carcinogenesis models in estimating u.s. populati...
23171878 - Invited commentary: circulating inflammation markers and cancer risk--implications for ...
24759568 - European cancer mortality predictions for the year 2014.
23758978 - Tailored rectal cancer treatment - a time for implementing contemporary prognostic fact...
23098468 - Mthfr c677t polymorphism and pancreatic cancer risk: a meta-analysis.
23409158 - The relationship between xrcc1 and xrcc3 gene polymorphisms and lung cancer risk in nor...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-22
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  -     ISSN:  1527-7755     ISO Abbreviation:  J. Clin. Oncol.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Mayo Clinic, Rochester, MN.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Computational phosphorylation site prediction in plants using random forests and organism-specific i...
Next Document:  Associations of Recreational Physical Activity and Leisure Time Spent Sitting With Colorectal Cancer...